comparemela.com

Latest Breaking News On - Professor ma jun - Page 1 : comparemela.com

BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),

United statesUnited kingdomGabrielle zhouLai wangKevin mannixMa junLymphoma research foundationChina national medical products administrationNational cancer instituteChinese society of clinical oncologyEnd results programAmerican cancer societySupervisor of supervisory committeeHarbin institute of hematology oncologyExchange commissionSupplemental new drug applications

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide . | May 6, 2023

United statesUnited kingdomMa junLai wangExchange commissionHarbin institute of hematology oncologySupervisor of supervisory committeeAmerican cancer societyEnd results programChinese society of clinical oncologyChina national medical products administrationNational cancer instituteLymphoma research foundationSupplemental new drug applicationsSupplemental applicationsGene beigene receives new approvals

Decarbonization in the United States and China: Fast and Furious Enough?

A “code red for humanity” that is how UN Secretary General António Guterres described the future climate scenarios laid out in the

T ai peiUnited statesFrance generalChina generalElij pattonGreta thunbergMa junUs development finance corporationInternational panel on climate change sixth assessmentWilson centerInternational renewable energy agencyBiden administrationWilson center china environment forumGeorge washington universityMajor economies forumTsinghua university

vimarsana © 2020. All Rights Reserved.